See Article on Page 18-22Compared with the general population, individuals with a previous colorectal cancer have an elevated risk of a second primary cancer [1, 2]. Possible reasons for this phenomenon could be (1) an overall greater predisposition to cancer due to the same environmental and genetic factors that contributed to the first primary cancer [3] and (2) the second cancers possibly being related to the effects of treatment for the first cancer [4].Lynch syndrome is an autosomal, dominant, inherited disorder of cancer susceptibility caused by germline mutations in DNA mismatch repair (MMR) genes. Mutation carriers are prone to developing cancers of the colon, rectum, endometrium, ovary, stomach, small intestine, urinary tract, kidney, biliary tract, and nervous system, and the diagnosis of these cancers generally occurs at a younger age than it does for non-MMR-related cancers [5]. Second cancers following colorectal cancer have essentially two types of patterns: Lynch-syndrome-associated cancers and cancers with no features of Lynch syndrome, which include breast, pancreas, prostate, and thyroid cancers [6-8].An increased surveillance strategy could lead to earlier identification and removal of both premalignant lesions and early-stage tumors. Any patients diagnosed with colorectal cancer at a young age are at high risk of having a second colorectal cancer and should be followed-up at regular intervals [6]. Furthermore, in surveillance of these patients, all Lynch-syndrome-related sites should be considered. However, given the limited evidence for the efficacy of screening for breast, pancreas, prostate, and thyroid cancers [8, 9], further studies are needed to verify the validity of screening for these cancers in Lynch syndrome.
Authors: Lois B Travis; Charles S Rabkin; Linda Morris Brown; James M Allan; Blanche P Alter; Christine B Ambrosone; Colin B Begg; Neil Caporaso; Stephen Chanock; Angela DeMichele; William Douglas Figg; Mary K Gospodarowicz; Eric J Hall; Michie Hisada; Peter Inskip; Ruth Kleinerman; John B Little; David Malkin; Andrea K Ng; Kenneth Offit; Ching-Hon Pui; Leslie L Robison; Nathaniel Rothman; Peter G Shields; Louise Strong; Toshiyasu Taniguchi; Margaret A Tucker; Mark H Greene Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: C Metayer; C F Lynch; E A Clarke; B Glimelius; H Storm; E Pukkala; T Joensuu; F E van Leeuwen; M B van't Veer; R E Curtis; E J Holowaty; M Andersson; T Wiklund; M Gospodarowicz; L B Travis Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Aung Ko Win; Noralane M Lindor; Joanne P Young; Finlay A Macrae; Graeme P Young; Elizabeth Williamson; Susan Parry; Jack Goldblatt; Lara Lipton; Ingrid Winship; Barbara Leggett; Katherine M Tucker; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Julie Arnold; A Joan Levine; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John L Hopper; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2012-08-28 Impact factor: 13.506
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Marcia Irene Canto; Michael Goggins; Charles J Yeo; Constance Griffin; Jennifer E Axilbund; Kieran Brune; Syed Z Ali; Sanjay Jagannath; Gloria M Petersen; Elliot K Fishman; Steven Piantadosi; Francis M Giardiello; Ralph H Hruban Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382